Join the Rybelsus group to help and get support from people like you.
Rybelsus News
Adverse Events From Semaglutide Seen in the ED Usually GI-Related
TUESDAY, April 15, 2025 – The rate of emergency department visits for adverse events among patients dispensed semaglutide is low, with most visits involving gastrointestinal effects, according to a...
Tirzepatide Dispensations Increased Rapidly After Approval
TUESDAY, April 15, 2025 – After approval, tirzepatide dispensations increased markedly among adults with type 2 diabetes prescribed glucose-lowering medications (GLMs) and among adults without...
Semaglutide Ups Risk for Nonarteritic Anterior Ischemic Optic Neuropathy in Diabetes
TUESDAY, April 8, 2025 – For patients with diabetes, semaglutide use is associated with an increased risk for nonarteritic anterior ischemic optic neuropathy (NAION), according to a study published...
ACC: Semaglutide Beneficial in Patients With T2DM and Peripheral Artery Disease
WEDNESDAY, April 2, 2025 – For patients with symptomatic peripheral artery disease and type 2 diabetes, semaglutide use is associated with increased walking distance, according to a study published...
Tirzepatide, Semaglutide Not Cost-Effective at Current Prices
WEDNESDAY, March 19, 2025 – Tirzepatide and semaglutide offer long-term health benefits but are not cost-effective, according to a study published online March 14 in JAMA Health Forum. Jennifer H....
GLP-1 RA Use Tied to Better Kidney Transplant Outcomes in Patients With Diabetes
TUESDAY, March 18, 2025 – Glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is associated with better graft and patient survival among kidney transplant recipients with diabetes, according to...
No Weight Loss Benefit Seen for Neoadjuvant Semaglutide Before Weight Loss Surgery
WEDNESDAY, March 12, 2025 – Neoadjuvant semaglutide before metabolic and bariatric surgery (MBS) is not beneficial in terms of weight loss, according to a research letter published online March 5 in...
Risk for Specific Hematologic Cancers Down With GLP-1 Receptor Agonist Use in T2DM
MONDAY, March 10, 2025 – For patients with type 2 diabetes (T2D), glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is associated with a reduced risk for developing hematologic cancers...
No Link Seen Between Preop GLP-1 Receptor Agonist Use and Postop Aspiration Pneumonia
THURSDAY, March 6, 2025 – Preoperative glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is not associated with short-term postoperative aspiration pneumonia, according to a study published...
Obesity On The Rise Worldwide, Report Says
TUESDAY, March 4, 2025 – More than half of adults and a third of children and teens worldwide will be overweight or obese by 2050, a comprehensive global analysis has concluded. Overweight and...
GLP-1 Receptor Agonist Use Not Linked to Increased Suicide Risk
MONDAY, March 3, 2025 – Glucagon-like peptide-1 (GLP-1) receptor agonists are not associated with an increased risk for suicidality compared with dipeptidyl peptidase-4 (DPP-4) inhibitors or...
Semaglutide May Reduce Craving in Alcohol Use Disorder
FRIDAY, Feb. 28, 2025 – Low-dose semaglutide seems to reduce craving and certain drinking outcomes in alcohol use disorder (AUD), according to a study published online Feb. 12 in JAMA Psychiatry....
Depression Risk Lower With GLP-1 Receptor Agonists Versus DPP-4 Inhibitors in Seniors
MONDAY, Feb. 24, 2025 – For older adults with type 2 diabetes (T2D), use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with a modestly lower risk for depression compared...
Certain Glucose-Lowering Meds Associated With Lower Risk for COPD Exacerbations
FRIDAY, Feb. 21, 2025 – For patients with type 2 diabetes (T2D) and chronic obstructive pulmonary disorder (COPD), sodium-glucose cotransporter-2 inhibitors (SGLT-2is) and glucagon-like peptide-1...
Senators Call on FDA to Act Against Misleading Weight-Loss Drug Commercials
WEDNESDAY, Feb. 12, 2025 – Commercials run by the telehealth company Hims & Hers have been placed under the microscope as lawmakers are calling out advertisement of prescription of injectable...